Meeting
2020 ASCO Virtual Scientific Program
Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Authors
Joline Si Jing Lim
National University Cancer Institute, Singapore, Singapore
Joline Si Jing Lim , Andrea Wong , Samuel Guan Wei Ow , Natalie Ngoi , Yvonne Li'en Ang , Gloria Chan , Lim Siew Eng , Wan Qin Chong , Joan Choo , Matilda Lee , Hon Lyn Tan , Yi-hua Jan , Kien Thiam Tan , Raghav Sundar , David Shao Peng Tan , Ross A. Soo , Cheng Ean Chee , Wei-Peng Yong , Boon C. Goh , Soo-Chin Lee
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT02562118
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1019)
DOI
10.1200/JCO.2020.38.15_suppl.1019
Abstract #
1019
Poster Bd #
104
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
First Author: Joline Si Jing Lim
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
First Author: Matthew H. Taylor
Poster
2014 ASCO Annual Meeting
E7080 (lenvatinib) in addition to best supportive care (BSC) versus BSC alone in third-line or greater nonsquamous, non-small cell lung cancer (NSCLC).
First Author: Libor Havel
Poster
2023 ASCO Annual Meeting
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
First Author: Shubham Pant